The agreement gives Pfizer exclusive rights outside Greater China to develop, manufacture, and commercialize the three programs. None of them has reached the investigational new drug (IND) stage yet. Pfizer can also use Starna’s in vivo CAR-T technology in inflammation and immunology and in oncology. The deal also includes options to license compounds from a separate research collaboration and to extend Pfizer’s rights to Greater China.

Conventional CAR-T therapies are made by taking a patient’s own T cells, modifying them outside the body, and infusing them back. In vivo approaches instead use RNA medicines to reprogram immune cells directly inside the body.

The New York-based drugmaker will lead clinical development outside Greater China. It plans to make the finished drug product for the first clinical trials at its US facilities.

Michael Vincent, Chief Inflammation & Immunology Officer at Pfizer, calls in vivo CAR-T “an emerging and promising approach for treating autoimmune diseases.”

“Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna’s in vivo CAR-T programs and technology give us a powerful way to pursue these approaches,” he says.

“We believe our proprietary targeted LNP delivery platform and RNA technology provide a strong foundation for advancing in vivo CAR-T therapies,” says Rongkuan Hu, CEO of Starna Therapeutics.